• Meridian Bioscience Inc's (NASDAQ: VIVO) subsidiary Magellan Diagnostics Inc has expanded the Class I recall of its LeadCare Test Kits used to detect lead in whole blood.

• Magellan provides two controls in the test kits designed to mimic blood and are spiked with lead to specific target values with an associated acceptable range.

• Results of the control tests within the acceptable range indicate that the system is operating properly before testing patient samples.

• In May 2021, Magellan initiated this voluntary recall after identifying an ongoing issue with testing of the controls included in the LeadCare Test Kits.

• Magellan received reports that control tests of either the "Low-Control" and/or the "High-Control" generated a "low" result.

• Impacted LeadCare Test Kits lots could potentially underestimate blood lead levels when processing patient blood samples.

• Related content: Benzinga's Full FDA Calendar.

• Price Action: VIVO stock closed 1.73% higher at $20.59 on Wednesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Assembly Bio Stock Tumbles On Discontinuation Of Hepatitis B Trial

• Pfizer Commences Dosing In Pivotal Oral COVID-19 Drug Trial

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.